Pharmacyclics, Inc. (Nasdaq: PCYC) announced data from three Chronic Lymphocytic Leukemia (CLL) presentations at the American Society of Hematology (ASH) Annual Meeting describing the Btk-selective inhibitor PCI-32765. Two presentations report preclinical data, and one presentation reports...